Early primary progressive MS. A new drug called ocrelizumab (Ocrevus) became available for primary progressive MS in 2024. It's an infusion you have every six months. To get it you must be early on in your primary progressive MS. Depending on your level of disability, 'early' means it's been between years since your MS began.
Potential drug treatment options throughout the course of relapsing remitting multiple sclerosis (MS). Primary and secondary progressive MS are not shown because there is no treatment available for primary progressive MS, and interferon -1b is the only drug approved for the treatment of secondary progressive MS. MRI = magnetic resonance
Potential drug treatment options throughout the course of relapsing remitting multiple sclerosis (MS). Primary and secondary progressive MS are not shown because there is no treatment available for primary progressive MS, and interferon -1b is the only drug approved for the treatment of secondary progressive MS. MRI = magnetic resonance
Later on, the company plans to submit its drug for primary and secondary progressive MS in the first half of 2024. Sanofi estimates there are, respectively, around 900,000, 120,0,000 patients diagnosed with relapsing, primary progressive and secondary progressive MS, and that the global market opportunity in MS exceeds 20 billion
Ocrevus (ocrelizumab) is a disease modifying drug treatment for relapsing remitting and early primary progressive MS.
Disease-modifying treatments Medications Clinically isolated syndrome Relapsing-remitting MS Secondary progressive MS and progressive relapsing MS Primary
New disease-modifying therapies Ocrelizumab (Ocrevus): This drug treats relapsing forms of MS and primary progressive MS (PPMS). Fingolimod (Gilenya): This
Ocrevus is a disease modifying drug for active relapsing remitting, very active relapsing remitting MS and early, inflammatory primary progressive MS.
Ocrevus (ocrelizumab) is a disease modifying drug treatment for relapsing remitting and early primary progressive MS.
Comments